CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
Levonorgestrel +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00445887
NCT00445887Phase 2Completed
CompareCT.gov

Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer

Gynecologic Oncology Group·interventional·Posted Mar 9, 2007·Updated Nov 19, 2019

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Levonorgestrel, and 1 other intervention for Ovarian Carcinoma. Completed, enrolled 60 participants across 66 sites.

Detailed Summary

This randomized phase II trial is studying how well levonorgestrel works in preventing ovarian cancer in patients at high risk for ovarian cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of levonorgestrel may prevent ovarian cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 9, 2007
Enrollment StartMar 10, 2008
Primary CompletionDec 11, 2013
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 19.3 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Levonorgestreldrug

Given orally

Placeboother

Given orally